Taylor J E, Coy D H, Moreau J P
Biomeasure Inc, Hopkinton, MA 01748.
Life Sci. 1988;43(5):421-7. doi: 10.1016/0024-3205(88)90521-8.
The in vitro binding of [125I-Tyr11]somatostatin-14 (SRIF-14) to membranes prepared from cultured human small cell lung carcinoma (SCLC) cells (NCI-H69) has been characterized. Binding to SCLC was monophasic and of high affinity (Kd = 0.59 +/- 0.02 nM, n = 3). The estimated Bmax was 173 +/- 2.4 fmol/mg protein. Receptors were also present on solid NCI-H69 tumors grown in vivo in the athymic nude mouse. However, the concentration was only about 10% of that observed in cell culture. Biologically-active SRIF analogues were potent inhibitors of [125I-Tyr11]SRIF-14 binding, and an analysis of the pharmacological specificity indicated that the SCLC receptor was of the peripheral (e.g., non-neural) subtype. The presence of SRIF receptors on SCLC membranes may indicate that SRIF has a role in regulation of SCLC function.
已对[125I-酪氨酸11]生长抑素-14(SRIF-14)与培养的人小细胞肺癌(SCLC)细胞(NCI-H69)制备的膜进行体外结合特性研究。与SCLC的结合呈单相且亲和力高(Kd = 0.59±0.02 nM,n = 3)。估计的Bmax为173±2.4 fmol/mg蛋白质。在无胸腺裸鼠体内生长的实体NCI-H69肿瘤上也存在受体。然而,其浓度仅约为细胞培养中观察到浓度的10%。具有生物活性的SRIF类似物是[125I-酪氨酸11]SRIF-14结合的有效抑制剂,药理学特异性分析表明SCLC受体属于外周(如非神经)亚型。SCLC膜上SRIF受体的存在可能表明SRIF在SCLC功能调节中起作用。